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Abstract
The nematode Caenorhabditis elegans has recently been developed as a host model for the study of Staphylococcus aureus virulence and
pathogenesis. Here, the toxicity and virulence of representative clinical isolates of our methicillin-resistant S. aureus (MRSA) epidemic
strains were studied using this model. The strains USA300 (associated with community infection outbreaks), USA400 (associated with
sporadic community infections) and CMRSA2 (associated with both hospital and community infections), as well as the nematocidal refer-
ence strain NCTC8325, showed high nematocidal activity, both by killing the majority of the nematodes (> 90%) over 9 days, and by
inhibiting second-generation nematode growth. By contrast, the typical hospital-associated MRSA strain CMRSA6, the colonization strain
M92, and the non-pathogenic Staphylococcus epidermidis control strain ATCC12228 were non-toxic to the nematode, which behaved
normally. The absence of nematocidal activity does not reﬂect lack of growth or reduced growth of the bacterial inoculum. The two
non-nematocidal strains share similar genomic backgrounds, bacterial growth curve patterns and virulence gene proﬁles. However, the
nematocidal strains each showed the same low maximum density growth curve patterns, but possessed distinct genetic proﬁles; no
common virulence gene patterns or speciﬁc genes have been elucidated. Our ﬁndings demonstrate that community-associated MRSA
strains are more pathogenic than hospital-associated MRSA in the C. elegans model and support the use of this model for studying the
virulence of S. aureus strains.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a leading
cause of healthcare- and community-related infection world-
wide. However, community-associated MRSA (CA-MRSA),
causing infections in healthy populations, has become a major
public health concern in North America in recent years [1–
3]. Community-related MRSA is associated with increased
disease severity, ranging from cutaneous abscesses to deadly
necrotizing pneumonia [4–7]. There are two dominant
CA-MRSA strains, USA300 and USA400, in North America.
The USA400 strain is associated with severe and rapidly fatal
infections, but is less frequently observed [1,8,9], whereas
USA300 appears to be highly epidemic and predominantly
associated with community-onset skin and soft-tissue infec-
tions [2,3,10,11], necrotizing pneumonia and other rapidly
progressive life-threatening infections [6]. Currently, there
are 10 major epidemic MRSA strains in Canada (CMRSA
1–10) [12]. Of these strains, CMRSA1, 3–6, 8 and 9 are typi-
cally hospital-associated (HA-MRSA), and CMRSA7 and
CMRSA10, corresponding to strains USA400 and USA300,
respectively, are commonly CA-MRSA. CMRSA2 is associ-
ated with both hospital and community infections [13].
The nematode Caenorhabditis elegans has been developed
as a host model for studying the pathogenicity of S. aureus
[14] and has been used in high-throughput screens for viru-
lence factors in S. aureus [15]. We studied the virulence of
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representative clinical isolates from our major local MRSA
epidemic strains and demonstrate for the ﬁrst time that
CA-MRSA strains are more virulent than HA-MRSA in a
C. elegans model, thus supporting the use of C. elegans as an
efﬁcient host model for studying the virulence and pathoge-
nicity of natural populations of S. aureus strains.
Materials and Methods
Laboratory-based surveillance in the Calgary Health Region
The Calgary Health Region (CHR) is one of Canada’s largest
integrated urban healthcare regions. It provides medical ser-
vices for a population of approximately 1.3 million people
and is serviced by a centralized diagnostic microbiology labo-
ratory, Calgary Laboratory Services (CLS). All new isolates
of MRSA (deﬁned as isolates with no previous history of
MRSA infection/colonization within a 1-year period prior to
their isolation) recovered at CLS from patients infected and/
or colonized in the CHR over a 7-year period (1 January
2000 to 31 December 2006) were included in this study. For
this analysis, isolates were separated into two categories
based on the anatomic sites from which they were taken,
which included clinically signiﬁcant sites (blood, wound, spu-
tum, bone, graft, sterile ﬂuid, urine and eye) and colonization
sites (nose, rectum, vagina, skin).
Bacterial strains, phenotypic and genotypic characterization
of isolates
The Canadian epidemic MRSA reference strains CMRSA1–10
were provided by the National Microbiology Laboratory,
Canada [12]. Methicillin-susceptible S. aureus (MSSA) strain
NCTC 8325 and Staphylococcus epidermidis strain ATCC
12228 were used as positive and negative nematocidal con-
trols, respectively, in the C. elegans assay. The colonization
strain M92 is a strain showing local nasal colonization and has
not been associated with infection over the course of many
years. The staphylococcal and MRSA isolates were identiﬁed
by standard procedures as previously described [16].
All new MRSA isolates were assayed by DNA ﬁngerprint-
ing, using pulsed-ﬁeld gel electrophoresis (PFGE), and a
strain proﬁle (CMRSA1–10 and unassigned types) was
assigned according to the Canadian standardized protocol
[12,17]. Selected representative isolates were tested for
Panton–Valentine leukocidin (PVL) genes [18] and character-
ized by staphylococcal cassette chromosome mec (SCCmec)
typing [19], multilocus sequence typing (MLST) [20], staphy-
lococcal protein A (spa) typing [21] and accessory gene
regulator (agr) typing [22]. Genetic proﬁles, based on 33
common S. aureus virulence genes, were determined by PCR
using previously described or newly designed primer pairs
(Table 1).
C. elegans maintenance and survival assays
Bristol N2 C. elegans nematodes were maintained at room
temperature (RT) on nematode growth medium plates
spread with Escherichia coli strain OP50 as a food source and
manipulated using established techniques [23]. C. elegans sur-
vival assays were performed as previously described [14].
Survival was monitored every 24 h over a 9-day period. For
population growth experiments, all worms were maintained
on the original plates throughout the experiment and the
accumulated numbers of live larval and adult nematodes
were scored by counting the live worms outside the bacte-
rial lawn. Plates with heat-killed bacteria were prepared as
previously described [24]. The experiments were performed
using 30 nematodes per experiment for individual strains and
repeated at least three times. Data were analysed by the
Kaplan–Meier method for adult nematode survival rate, and
by the log-rank test for comparison of signiﬁcant survival
differences using GraphPad Prism (GraphPad Software, Inc.,
La Jolla, CA, USA).
Bacterial quantitation and growth curves
For quantitating bacterial viability in the presence of nalidixic
acid (NA) during the C. elegans survival assays, 59 lL of
overnight bacterial culture (OD600 = 0.28) were spread on
8.5-cm diameter tryptic soy agar (TSA) plates with or with-
out 5 lg/mL NA. Two circular pieces of agar 0.5 cm in diam-
eter (0.2 cm2) were punched from the bacterial lawn on
days 1, 5 and 9; these were rinsed and the bacteria re-
suspended in 1 mL brain–heart infusion (BHI). Live bacteria
were quantiﬁed by serial dilution and plating. To determine
if the NA had any effect on bacterial growth, bacteria
harvested on days 1 and 9 from the above TSA and NA-TSA
plates were inoculated into 1 mL BHI (initial OD600 = 0.07),
and their growth rate measured over the subsequent 8 h at
37 C, using an automatic density measuring machine 1420
Multilabel Counter VICTOR (Perkin Elmer).
Results
Epidemiology of major clonal epidemic MRSA strains in the
CHR during 2000–2006
Between 2000 and 2006, the number of newly diagnosed cases
of MRSA infection and colonization in the CHR gradually
increased from year to year (Fig. 1a), with CMRSA2 being the
predominant strain isolated. The USA300 strain emerged in
2001 and became established as the predominant strain from
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2005. USA400 and CMRSA6 were the other major strains iso-
lated, although their frequencies were lower. Other CMRSA
clonotypes accounted for < 5% of all isolates (Fig. 1a).
Analysing the association between the major strains and
clinically signiﬁcant anatomical sites of isolation (Fig 1b), the
CA strains USA300, USA400 and CMRSA2 were associated
with invasive anatomic sites and represented, respectively,
776 of 858 (90.4%), 169 of 197 (85.8%) and 827 of 1125
(73.5%) of the isolates. However, for the typical HA-MRSA
strain CMRSA6, 34 of 48 (70.8%) isolates were associated
with invasive anatomic sites. Three isolates from each of the
four major local epidemic strains (USA300, CMRSA2,
USA400 and CMRSA6), together with a local nasal colonizing
clone M92, were selected for further testing.
Genotypic and phenotypic characterization of MRSA
isolates
Molecular typing revealed that each of the six strains had
unique genetic proﬁles (Fig. 2). All USA300 isolates carried
the SCCmec type IVa element and PVL genes, and shared
the same MLST type ST8, belonging to the clonal complex
(CC) 8, spa type t008 and agr type I. The USA400 isolates
also carried SCCmec IVa and PVL, but were ST1 (CC1), spa
t128 and agr III, and the CMRSA2 strains carried SCCmec II
but not PVL, and were ST5 (CC5), spa t002 and agr II.
CMRSA6 and M92 strains were MLST type ST239 (CC8), agr I,
and lacked PVL genes, but differed in SCCmec type and spa
type in that CMRSA6 strains carried SCCmec III and
spa t037, whereas M92 carried SCCmec II and a non-typable
spa type. The MSSA strain NCTC8325 showed a PFGE pat-
tern similar to that of USA300 and possessed ST8, spa t211
and agr I (Fig. 2). All isolates from the same group tended to
have the same antibiotic resistance proﬁles (Fig. 2). Strains
CMRSA2, CMRSA6 and M92 showed typical HA-MRSA mul-
tiple drug-resistance patterns, whereas strains USA300 and
USA400 demonstrated typical CA-MRSA antibiotic resistance
proﬁles (Fig. 2).
MRSA strains show differential killing activity against
C. elegans
Clinical isolates of MRSA, representative of the different
strains, showed completely different killing activities in the
C. elegans host model. Strains NCTC8325 and ATCC12228
were included as positive and negative nematocidal reference
strains. The NCTC8325 strain, which showed nematocidal
activity in a previous study [14], was also toxic in our experi-
ments, killing 70.3%, 93.4% and 96.7% of worms by days 3, 6
and 9, respectively. By contrast, the ATCC12228 strain did
not show nematocidal activity (Fig. 3a).
Strains USA300, USA400 and CMRSA2 demonstrated
nematocidal activity after 24 h. The mean killing rates for the
three strains were, respectively, 69.3%, 57.3% and 51.4% by
day 3, 92.7%, 91.9% and 95.7% by day 6 and 97.2%, 91.9%
(a)
(b)
FIG. 1. Epidemiology of major clonal epidemic methicillin-resistant
Staphylococcus aureus (MRSA) strains in the Calgary Health Region
from 2000 to 2006. (a) The trend-line denotes the yearly gradual
increase in the number of newly diagnosed cases of MRSA infection/
colonization (left axis). Relative yearly frequencies of pulsed-ﬁeld gel
electrophoresis (PFGE) clonotypes of MRSA are shown by bars
(right axis). CMRSA1–10 are the major epidemic MRSA clonal
groups in Canada. (b) USA300 (CMRSA10), USA400 (CMRSA7) and
CMRSA2 isolates were collected from invasive anatomic sites more
often than CMRSA6 over the 7-year period (01.01.2000–
31.12.2006). Clinically signiﬁcant sites (invasive anatomic sites)
included blood, wound, sputum, bone, graft, sterile ﬂuid, urine and
eye. Colonization sites included the nose, rectum, vagina and skin.
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FIG. 2. Genotypic and phenotypic characteristics of methicillin-resistant Staphylococcus aureus (MRSA) isolates. Molecular typing revealed unique
genetic proﬁles for the ﬁve MRSA strain types/clonal groups, with identical genotypic characteristics observed among isolates within each clonal
group. A. NCTC8325 is a nematocidal reference MSSA strain. CMRSA2, 6, 7 and 10 are Canadian major epidemic MRSA reference strains 2, 6,
7 and 10 (corresponding to other common names of strains: USA100/800/NewYork, Brazilian/Hungarian or EMRSA1/4/11, USA400 and USA300,
respectively); the other strains were from local clinical isolates. PVL, Panton–Valentine leukocidin (+, positive; ), negative); SCCmec, staphylococ-
cal cassette chromosome mec; agr, accessory gene regulator; spa (staphylococcal protein A gene) motif: t008 (YHGFMBQBLO), t211
(YHGGFMBQBLO), t128 (UJJFKBPE), t002 (TJMBMDMGMK), t037 (WGKAOMQ), NT (non-typable); MLST (multilocus sequence typing) proﬁle:
ST8 (3-3-1-1-4-4-3), ST1 (1-1-1-1-1-1-1), ST5 (1-4-1-4-12-1-10), ST239 (2-3-1-1-4-4-3); CC, clonal complex; Pen, penicillin; Oxa, oxacillin; Ery,
erythromycin; Clin, clindamycin; Gen, gentamicin; Cip, ciproﬂoxacin; Tet, tetracycline; Rif, rifampin; Tri/Sul, trimethoprin-sulfamethoxazole; Van,
vancomycin; S, susceptible; R, resistant; N/A, not applicable; ND, not done.
(a)
(b) (c)
(d) (e)
FIG. 3. Methicillin-resistant Staphylococcus aur-
eus (MRSA) strains demonstrate differential
killing activity against Caenorhabditis elegans.
(a) Kaplan–Meier survival plots of nematodes
fed NCTC8325 (n = 120) and MRSA clinical
isolates USA300–2406 (n = 120), USA400–
8830 (n = 120), CMRSA2–849 (n = 120),
CMRSA6–1777 (n = 120) and M92 (n = 120).
Staphylococcus epidermidis ATCC12228 (n =
90). The survival curves of NCTC8325,
USA300–2406, USA400–8830, CMRSA2–849
are signiﬁcantly different from those of
CMRSA6–1777, M92 and ATCC12228. (b–e)
Three clinical isolates within a clonal group
demonstrated similar levels of killing acti-
vity: (b) USA300 isolates (2406, 5391 and
CMRSA10; n = 90 each; p = 0.799);
(c) USA400 isolates (8830, 2772 and CMRSA7;
n = 90 each; p = 0.156); (d) CMRSA2 isolates
(849, 1938 and CMRSA2; n = 90 each; p =
0.347); (e) CMRSA6 isolates (1777, 086 and
CMRSA6) and M92 (n = 90 each; p = 0.480).
CMRSA2, 6, 7 and 10 are the Canadian major
epidemic MRSA reference strains; other strains
are from local clinical isolates.
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and 99.0% by day 9 (Fig. 3a). Although the USA300 strain
demonstrated rapid nematocidal activity, there were no
signiﬁcant differences between these three strains over the
9-day experiment. By contrast, the strains CMRSA6 and M92
did not show any nematocidal activity and their survival
curves differed signiﬁcantly from those of the other nemato-
cidal strains (p £ 0.0001) (Fig. 3a). Moreover, the nematocidal
activities of the USA300, USA400 and CMRSA2 strains were
abolished when the worms were fed with heat-killed isolates
(data not shown), suggesting that killing requires the pres-
ence of live bacteria [14]. An additional two clinical isolates
from each clonal group were tested and demonstrated simi-
lar killing activity to other isolates from the same clonal
group (Fig. 3b–e). These results conﬁrmed that USA300,
USA400 and CMRSA2 strains were pathogenic to C. elegans,
whereas CMRSA6 and M92 were non-pathogenic.
MRSA strains demonstrated differential effects on
nematode population growth, reproduction and survival
Nematodes progress through four larval stages (L1–L4)
before maturing into egg-laying adults. We observed differen-
tial effects of different MRSA strains on nematode survival
and reproduction. Strains ATCC12228, CMRSA6 and M92
killed neither L4 larval nor adult nematodes; nematodes
behaved normally on plates spread with these strains
(Fig. 4d, e), appearing similar to those cultured on normal
FIG. 4. Differential effect of various methicillin-resistant Staphylococcus aureus (MRSA) strains on Caenorhabditis elegans survival and population
growth. Representative images of C. elegans feeding on MRSA strains (a) USA300, (b) USA400, (c) CMRSA2, (d) CMRSA6 and (e) M92, taken on
day 3. Most C. elegans adults and larvae were killed by strains USA300, USA400 and CMRSA2, but not by ATCC12228, CMRSA6 and M92. (a–c)
Dead adults, eggs, dead larvae and a few early-stage (young) larvae were most often seen on plates of USA300, USA400 and CMRSA2. (d, e) By
contrast, live adults, eggs and all (variant) stage (L1–L4) live larvae were seen on the CMRSA6 and M92 plates. The dead adults appeared as
‘ghosts’ in the bacterial lawn, because the internal cellular ultrastructure was lost (a–c). Worms that died in the earlier stages of adulthood
showed smaller mean lengths (a, c) than those that died in the later stages (b) compared with live mature adults (d, e). The differential effects of
various MRSA strains on nematode population growth during the 9-day experimental period were estimated for (f) larvae and (g) adult worms.
Strains NCTC8325, USA300, USA400 and CMRSA2 efﬁciently killed adults and larvae, thereby inhibiting second-generation growth; a number of
live adults remained from the initially seeded worms (g). However, as the eggs continued to hatch, there were always ‡ 30–50 larvae on the
lawns of USA300, USA400 and CMRSA2 (f). By contrast, as a result of the avirulence of strains ATCC12228, CMRSA6 and M92 in C. elegans,
the number of live larvae and, subsequently, live adults sharply increased on days 2 and 4 and reached a limit of approximately 2000 worms on
day 6 for (f) larvae and (g) adults, respectively. Original magniﬁcation ·100. The number of worms at the y-axis is in log scale. Numbers of live
larvae and adult worms on ATCC12228, CMRSA6 and M92 plates are conservative estimates.
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E. coli-OP50 feeding plates (data not shown) producing a
large number of second- and even third-generation larvae
and adult nematodes (Fig. 4f, g). By contrast, isolates of
NCTC8325, USA300, USA400 and CMRSA2 not only killed
the seeded nematodes, but also efﬁciently killed the early
larval stage worms and, therefore, inhibited proliferation of
second-generation nematodes (Fig. 4a–c, f, g).
Different MRSA strains possess distinct virulence gene
proﬁles
To test if the nematocidal and non-nematocidal MRSA strains
possess distinct virulence gene proﬁles, we performed PCR
assays of 33 virulence genes (Table 1). No common virulence
gene pattern or possession of speciﬁc genes was noted
amongst the killing or non-killing MRSA strains (Table 1).
Interestingly, two non-nematocidal strains, CMRSA6 and
M92, which share similar genetic backgrounds (Fig. 2), pos-
sess identical virulence gene proﬁles (Table 1), which sug-
gests that they are more closely related to each other than
to the nematocidal strains.
NA-supplemented TSA plates did not quantitatively affect
bacterial growth
To exclude the possibility that the non-nematocidal activity of
CMRSA6 and M92 strains was caused by the death of bacteria
or the NA effect, we compared the bacterial viability and
growth of MRSA strains on TSA and NA-TSA plates on assay-
ing growth on days 1, 5 and 9 (Fig. 5). For all strains except
USA400 (p = 0.007), there was no signiﬁcant difference in
CFU counts between TSA and NA-TSA plates on day 1
(Fig. 5a–e). Moreover, there was no difference in CFU counts
between any of the MRSA strains on TSA and NA-TSA plates
at any of the three time-points (days 1, 5 and 9) (Fig. 5f, g).
Distinct bacterial growth curve patterns in nematocidal and
non-nematocidal MRSA strains
We tested and compared the growth characteristics
of MRSA strains by measuring their growth on TSA and
NA-TSA plates; no differences were noted in the effect of
NA on the different strains (Fig. 6). Interestingly, two distinct
bacterial growth curve patterns were observed in the nema-
tode-killing strains (USA300, USA400 and CMRSA2) and the
non-killing strains (CMRSA6 and M92), regardless of NA sup-
plementation, whereby the former group always had the
lower maximum densities but no extended lag phase when
compared with the latter strains (Fig. 6f–i).
Discussion
Sifri and co-workers [14] introduced C. elegans as a host
model for studying the pathogenicity and virulence of S. aur-
eus and demonstrated distension of the digestive tract and
the death of worms over 2–7 days. This group tested only a
few clinical MRSA isolates, of which one strain had marginal
killing activity. In the present study, we adopted the C. ele-
gans model to test our local dominant epidemic strains, and
found that USA300, USA400 and CMRSA2 are signiﬁcantly
more pathogenic than CMRSA6.
This correlates with the ﬁnding that the nematocidal
strains were more often collected from invasive anatomic
sites than CMRSA6. CMRSA2 and CMRSA6 were isolated
from invasive sites with similar frequencies (73.5% vs. 70.8%,
respectively), but this may reﬂect the heterogeneity of
CMRSA2, which may indicate a hospital- or community-asso-
ciated pattern. A previous study also provided evidence that
CA-MRSA isolates tend to be more virulent than some
(a)
(f) (g)
(b) (c) (d) (e)
FIG. 5. Nalidixic acid (NA) supplementation
did not quantitatively affect bacterial growth
over the 9-day experimental period. (a–e)
CFU counts per 0.2 cm2 plug of agar for each
strain when grown on tryptic soy agar (TSA)
vs. NA-TSA plates on days 1, 5 and 9, respec-
tively. CFU counts for each strain grown on
TSA vs. NA-TSA plates were not statistically
different (all p ‡ 0.08 except USA400 on
day 1; p = 0.007). (f, g) Comparison of CFU
counts among different strains grown on both
TSA and NA-TSA plates on days 1, 5 and 9
(all p ‡ 0.06). NA-TSA, TSA plates supple-
mented with 5 lg/mL nalidixic acid.
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HA-MRSA strains in animal models and in vitro tests [25].
Furthermore, although C. elegans is an invertebrate host, the
correlation between the nematocidal activity of MRSA and
the isolation of MRSA from clinically relevant invasive
anatomic sites vs. colonization sites suggests that C. elegans
is a robust model with which to study the pathogenesis of
MRSA.
Sifri et al. showed that most S. aureus strains, including
those with poor nematocidal activity, killed young larvae efﬁ-
ciently, such that no nematode population growth occurred
under their assay conditions [14]. By contrast, our studies
demonstrate that local epidemic MRSA strains show different
killing activities against C. elegans, with CMRSA6 and M92
demonstrating lack of killing activity against adults and young,
thus allowing second- and even third-generation worms to
appear during the experiment (Fig. 4). Our experiments also
showed that the non-killing did not reﬂect bacterial death or
reduced ﬁtness.
Using a variety of molecular typing methods, we deter-
mined the genetic background and evolutionary relationships
FIG. 6. Nematode-killing and non-killing methicillin-resistant Staphylococcus aureus (MRSA) strains show distinct bacterial growth curve patterns,
regardless of nalidixic acid (NA) supplementation and time. (a–e) Comparisons of growth curves for each strain after plating on tryptic soy agar
(TSA) and NA-TSA on days 1 and 9. NA did not signiﬁcantly affect bacterial growth curves over the 9-day period, although the growth phase
characteristics differed between days 1 and 9 for each strain by extended lag phase growth on day 9 (mean extended lag phase time: 3, 3, 6, 5,
4 h for USA300, USA400, CMRSA2, CMRSA6 and M92, respectively) and lower maximum densities in stationary phase on day 9 (mean differ-
ence of maximum density OD600 between days 1 and 9: 0.10, 0.29, 0.07, 0.11, 0.24 for USA300, USA400, CMRSA2, CMRSA6 and M92, respec-
tively). (f–i) Comparison of growth curves for different strains on TSA and NA-TSA plates on days 1 and 9. The nematode-killing strains
(USA300, USA400 and CMRSA2) always had lower maximum densities but no extended lag phases compared with the non-killing strains
(CMRSA6 and M92). Mean maximum OD600 was 0.42, 0.53 and 0.42 for USA300, USA400 and CMRSA2, respectively, vs. 0.63 and 0.72 for
CMRSA6 and M92, respectively, on day 1, and 0.36, 0.24, 0.35 for USA300, USA400 and CMRSA2, respectively, vs. 0.52 and 0.48 for CMRSA6
and M92, respectively, on day 9. NA-TSA, TSA plates supplemented with 5 lg/mL nalidixic acid; Blank, bacteria-free medium control.
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between these clinical isolates of four MRSA stains (Fig. 2).
CMRSA6 and M92 actually possess similar genetic back-
grounds. By contrast, strains USA300, USA400 and CMRSA2
have unique genetic proﬁles. These ﬁndings suggest that the
virulence of MRSA in C. elegans may be determined by the
strain’s speciﬁc genetic background. We determined the pro-
ﬁles of the 33 most common virulence genes in different
clones and found that different MRSA strain groups pos-
sessed distinct virulence gene proﬁles (Table 1). Interestingly,
two non-nematocidal strains (CMRSA6 and M92) showed
identical virulence gene proﬁles, suggesting a close phyloge-
netic relatedness. However, no common virulence gene pat-
terns or speciﬁc genes were found to be associated with
pathogenicity of the nematocidal strains in the C. elegans
model. Previously, the virulence factors v8, agr, sarA and hla
were all shown to be important for C. elegans killing [14].
However, the killing strains showed different virulence gene
proﬁles and non-killing strains also carried v8 and a-haemoly-
sin. We were unable to draw any conclusions from the asso-
ciation between agr type and pathogenicity in C. elegans
because the nematode-killing strain (USA300) and non-killing
strains shared the same agr type I (Fig. 2).
Overall, our results suggest that the mechanism of C. ele-
gans killing by S. aureus is complex and no single factor
responsible for virulence has been identiﬁed to date. Rather,
multiple virulence factors or certain combinations of viru-
lence factors acting in concert may be responsible for the
nematocidal activity. This may be true in human hosts as well
as in other mammalian hosts and is an area for future study.
The observation that the nematocidal and non-nematocidal
strains showed two distinct bacterial growth patterns,
in which the nematocidal group always showed the lower
densities, suggests that proteins secreted by these strains
control the total bacterial number in the stationary phase
and is worthy of future study.
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